Clinical Trial Update: Cenobamate Open-Label Extension Study for YKP3089C025 [Phase 3]

View source ↗

Summary

Open-label extension study of cenobamate (YKP3089) for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy, currently enrolling by invi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Idiopathic Generalized Epilepsy

Drugs mentioned

• Cenobamate (cenobamate)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy | Phase 3 | Status: ENROLLING_BY_INVITATION